TOP > 外国特許検索 > ADULT T-CELL LEUKEMIA-LYMPHOMA DETECTION METHOD

ADULT T-CELL LEUKEMIA-LYMPHOMA DETECTION METHOD

Foreign code F200010236
File No. (S2019-0201-N0)
Posted date 2020年10月29日
Country 世界知的所有権機関(WIPO)
International application number 2020JP008206
International publication number WO2020179646
Date of international filing 令和2年2月28日(2020.2.28)
Date of international publication 令和2年9月10日(2020.9.10)
Priority data
  • 特願2019-037246 (2019.3.1) JP
Title ADULT T-CELL LEUKEMIA-LYMPHOMA DETECTION METHOD
Abstract An adult T-cell leukemia-lymphoma (ATL) detection method is provided which involves determining the presence or absence in a target biological sample of DNA methylation of at least one gene selected from the group consisting of SERPINB6, NELL2, THEMIS, ZSCAN18, LAIR1, CD7, RNF130, ZIK1, LYPD3, TMEM45B, POMC, FHIT, MDS2, HOOK1, SORCS3, C2orf40, ZNF662, SPG20, ZNF717, LZTFL1, KLHL34 and BCL9, wherein DNA methylation of at least one of the aforementioned genes indicates that the subject has developed or is at risk of developing ATL. By this means, a new detection method of adult T cell leukemia-lymphoma (ATL) is provided.
Outline of related art and contending technology BACKGROUND ART
Adult T cell leukemia/lymphoma (ATL) is a peripheral T cell tumor caused by infection of T cells with retrovirus Human T-cell Lymphotropic Virus type-1 (HTLV-1). HTLV-1 is mainly infected by lactation, sex, transfusion, and the like, and HTLV-1 infants are localized in Japan, Calib sea coastal countries, central Africa, South America, and the like, and are estimated to be 500 million persons and ~ 2,000 million persons as a whole. HTLV-1 infectants in Japan are estimated to be 110 million, and (non-patent documents 1) and 40 ~ 50 % are unevenly distributed in Kyushu and okinawa district, but in recent years, HTLV-1 infectants in metropolitan areas such as Osaka, Tokyo and Aichi tend to increase.
HTLV-1-infected T cells undergo a multistage carcinogenesis process, which acquires clonic proliferation ability while accumulating genetic mutations and epigenetic abnormalities. Therefore, (Non-Patent Document 1) is characterized in that the period from infection to onset of ATL is very long, and as a result, there are many ATL onset persons in elderly carriers. On the other hand, most of HTLV-1 infected patients end their life as asymptomatic infected patients, but 3 ~ 5 % of infected patients develop ATL, and their clinical pathologies are classified into sod, chronic, acute and lymphoma types. Acute and lymphoma types and some chronic types having poor prognosis factors have high malignancy and very poor prognosis. On the other hand, the chronic type which does not have the poor prognosis factor is considered to be low grade ATL which follows relatively slow progress, and direct therapeutic intervention is not basically performed. However, (Non-Patent Document 2), in which approximately half of the low grade ATL patients have acute conversion over the course and the long-term prognosis thereof is poor. Therefore, it is desired to develop effective methods for preventing and treating ATL onset.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • SAGA UNIVERSITY
  • OHARA PHARMACEUTICAL CO., LTD.
  • Inventor
  • WATANABE Tatsuro
  • SUEOKA Eizaburo
  • KIMURA Shinya
  • URESHINO Hiroshi
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は,下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close